Pentair (NYSE: PNR) 2026 Conference Call Summary Company Overview - **Company**: Pentair - **Date**: March 18, 2026 - **Focus**: Pool and Water Solutions segments Key Points Industry Exposure and Guidance - Pentair has no exposure to supply chain issues related to the Middle East, indicating stability in operations [12][14][18] - The company confirmed its guidance for Q1 and the full year, with no new updates since the Investor Day on March 4 [14][18] Pool Segment Insights - Approximately 80% of pool revenue comes from the existing install base, which is aging with an average age of 23 years [21][26] - The company expects flat volume in 2026 compared to 2025, with a slight price increase anticipated [22][34] - The repair and replacement cycle for pool equipment is expected to increase due to the aging install base, although no significant uptick is modeled for 2026 [26][34] - The average sales price for a full pool automation system is around $15,000 to distributors, with consumer prices ranging from $35,000 to $50,000 [42][44] - The attachment rate for automation upgrades is currently over 98% [48] Market Dynamics and Competition - Pentair does not anticipate a robust recovery in the residential market through 2028, with only modest volume and price growth expected [34][37] - The company maintains strong relationships with distributors and dealers, which is crucial for market positioning against lower-end products from competitors [98][99] - The total pool sales for the previous year were approximately $1.5 billion [110] Water Solutions Segment - The Water Solutions business includes residential water quality management and commercial water solutions, with a focus on brands like Everpure and Manitowoc [114][115] - The company has seen challenges in the quick-service restaurant sector but is optimistic about growth in convenience stores [115][127] - The commercial water business is expected to benefit from innovations and a stable growth trajectory, particularly in North America [121][122] Flow Segment Insights - The aging U.S. infrastructure presents opportunities for Pentair's commercial pump offerings, with an uptick in repair and replacement cycles noted [129] - The company is leveraging proprietary sustainable technologies to enhance its market position [130] Financial Outlook and Capital Allocation - Pentair aims for 100 basis points of margin expansion per year, targeting high single-digit operating profit growth [159] - The company is disciplined in capital allocation, considering stock buybacks and potential acquisitions based on value creation for shareholders [165][170] Additional Considerations - Pentair is focused on innovation and maintaining a competitive edge through new product development and customer service enhancements [60][74] - The company is actively managing pricing strategies to offset inflationary pressures, with no significant risks beyond current guidance [141][142] This summary encapsulates the key insights and strategic outlook for Pentair as discussed in the conference call, highlighting the company's focus on stability, innovation, and market positioning in the pool and water solutions sectors.

HSBC 2026 Conference Summary Company Overview - **Company**: HSBC (NYSE: HSBC) - **Date**: March 18, 2026 - **Speaker**: Pam Kaur, Group CFO Key Points Industry Context - The banking industry is currently facing challenges due to geopolitical tensions, particularly the conflict in the Middle East, which has raised concerns about operational continuity and customer safety [4][5][6]. Financial Performance and Targets - HSBC aims for a return on tangible equity (ROTE) target of over 17% and anticipates a growth trajectory of 5% between 2027 and 2028 [5][6]. - The Middle East region contributes approximately 5% to HSBC's profit before tax (PBT), with significant contributions from HSBC Bank Middle East ($1 billion) and Saudi Awwal Bank (31% share contributing $700 million) [4]. Risk Management - HSBC is monitoring various risks, including cyber threats and operational continuity, due to the ongoing conflict [5]. - The bank has not adjusted its expected credit loss (ECL) guidance, assuming a short-term impact from the conflict [5][6]. Private Credit Exposure - HSBC's exposure to private credit is less than 2% of its loan book, approximately $20 billion, with a minority being secondary exposures reliant on third-party due diligence [11][12]. Growth Strategies - HSBC is reallocating $1.8 billion in costs to strategic growth opportunities, particularly in Asia, and is focused on enhancing operational efficiencies across its four business segments [13][14]. - The bank is optimistic about growth in its wealth management business, leveraging its strong customer base and expanding product offerings [16][62]. Technology and AI Deployment - HSBC is investing in AI to enhance productivity and operational efficiency, with over 80% of employees utilizing a productivity suite [46][47]. - The bank aims to deploy AI in areas such as KYC onboarding and transaction monitoring to improve efficiency and customer experience [49][50]. Capital Management - HSBC maintains a disciplined approach to capital management, focusing on organic growth while being open to strategic acquisitions that align with its long-term goals [34][35]. - The bank emphasizes the importance of maintaining a strong balance sheet and liquidity position to support its operations and customer needs [75][76]. Market Opportunities - HSBC sees growth potential in the wealth management sector, particularly in emerging markets with growing middle classes, such as China and India [62]. - The bank is also exploring opportunities in digital assets and tokenized deposits, aligning with its strategy to enhance its digital offerings [69][70]. Conclusion - HSBC is committed to navigating current challenges while focusing on strategic growth, operational efficiency, and leveraging technology to enhance customer service and profitability [75][79].

Summary of Neurogene Conference Call Company Overview - **Company**: Neurogene - **Focus**: Development of genetic medicines for neurological diseases, particularly Rett syndrome [2][3] Core Points and Arguments - **Lead Program**: NGN-401 for Rett syndrome, a severe disorder primarily affecting girls, with a market opportunity estimated in the billions, targeting 15,000-20,000 patients in the U.S. and Europe [3][4] - **Clinical Trials**: The Phase 3 trial, named Embolden, is actively enrolling patients aged 3 and older who have completed the regression phase of the disease, with dosing expected to complete in Q2 of the current year [3][4] - **Regulatory Interaction**: Neurogene has regular interactions with the FDA, participating in the START Pilot program, which provides significant access and feedback on trial design [7][8] - **Trial Design**: The Embolden trial was designed in close collaboration with the FDA, incorporating feedback from multiple meetings to ensure alignment on key elements [8][9] - **Efficacy Data**: In the Phase 1/2 trial, 88% of participants showed improvement on the CGI-I score, with an average of 4 developmental milestones gained per participant [23][24] - **Safety Profile**: A hyper-inflammatory reaction was observed at a higher dose, leading to a reduction in dosage. Robust monitoring procedures are in place to manage potential adverse events [31][32] Important but Overlooked Content - **Statistical Success Threshold**: A 35% threshold for success has been established based on natural history data, requiring 7 out of 20 participants to be considered responders for statistical success [35] - **Market Dynamics**: The market for Rett syndrome treatments is large enough to accommodate multiple players, with Neurogene positioning NGN-401 as a best-in-class gene therapy product [38][39] - **Financial Position**: Neurogene has sufficient capital to fund key clinical and regulatory milestones through Q1 2028, ensuring a runway for upcoming catalysts [41]

Kimball Electronics Conference Call Summary Company Overview - **Company**: Kimball Electronics (NasdaqGS:KE) - **Industry**: Electronics Manufacturing, specifically in automotive, industrial, and medical sectors - **History**: Established over 65 years ago, spun out from Kimball International 11 years ago to become a publicly traded company [2][3] Core Markets - **Automotive**: Focus on steering and braking systems - **Industrial**: Climate controls and off-highway equipment, referred to as the "green and clean" vertical - **Medical**: Full assembly of medical devices, including drug delivery systems and surgical instruments; recently opened a state-of-the-art CMO facility in Indianapolis [3][4][5] Strategic Focus - **Shift to Healthcare**: Two years ago, Kimball made a strategic decision to focus more on the healthcare sector, leveraging its electronics and plastics molding capabilities to enhance supply chain stickiness and improve positioning with customers [6][7] - **Investment in Facilities**: The company is investing in state-of-the-art facilities to support its medical strategy, including a new facility in Indianapolis with cold chain and cleanroom capabilities [8][48] Financial Performance - **Q2 Results**: Reported a 15% growth in the medical segment, with growth across all geographies and multiple programs; other segments, particularly automotive, faced challenges due to the loss of a large program [21][22][23] - **Revenue Guidance**: Raised revenue guidance for the full year to approximately $1.4 billion, driven by growth in the medical vertical [26][25] - **Margin Improvement**: Gross margin improved due to operational efficiencies and cost management, with adjusted operating income margins expected to rise from 4%-4.5% to potentially 6%-7% in the long term [27][56][59] Competitive Differentiation - **Full Assembly Capability**: Kimball offers full and final assembly for medical customers, which is attractive as many customers prefer to focus on R&D rather than manufacturing [17][18] - **Unique Product Offerings**: Examples include auto-injectors with integrated electronics that provide user prompts, showcasing vertical integration and innovation [19][20] Key Growth Areas - **Drug Delivery Systems**: Significant growth potential in the auto-injector market, particularly with the rise of GLP-1 medications; the company sees opportunities beyond current known drugs [38][39] - **Microfluidics and Surgical Instruments**: Interest in smaller, more efficient medical devices that require advanced manufacturing capabilities [40] Customer Relationships - **Customer Concentration**: Philips is a key customer, contributing over 10% of revenue through multiple divisions; Kimball aims to maintain long-term relationships and expand offerings to existing customers [42][44] - **New Customer Acquisition**: The goal is to add approximately five new customers annually to refresh the portfolio and drive growth [44] Facility Expansion - **New Facility**: The recently opened 300,000 sq ft facility in Indianapolis is designed to support growth and demonstrate capabilities to customers, with options for further expansion [48][49][50] M&A Strategy - **Acquisition Criteria**: Focus on expanding geographies and adjacencies that complement existing capabilities; looking for opportunities that enhance the portfolio and customer relationships [52][53] Conclusion - **Long-term Outlook**: The company is optimistic about achieving higher operating income margins and overall growth, driven by strategic investments in healthcare and operational efficiencies [56][59]

Summary of General Motors Conference Call Company Overview - **Company**: General Motors (GM) - **Key Speaker**: Paul Jacobson, Chief Financial Officer Core Industry Insights - **Focus on Digital Revenue**: GM is emphasizing the growth of its OnStar digital platform, which is seen as a significant long-term opportunity for revenue expansion [1][4] - **Connected Vehicles**: The company is transitioning from traditional vehicle sales to a model that includes ongoing revenue from connected services, targeting not just initial sales but also subsequent owners of vehicles [7][8] - **Software Margins**: The margins from software services in the connected business are expected to surpass those from traditional vehicle sales over time [9] Financial Highlights - **Deferred Revenue Growth**: GM anticipates that its deferred revenue will approach $7.5 billion by 2026, with a significant portion already locked in from subscriptions [22][27] - **Recognized Revenue**: The company expects to recognize approximately $3 billion in revenue this year, with a focus on converting prepaid customers to subscription services [27][22] - **Customer Engagement**: Over 50% of customers are upgrading from the basic OnStar package to premium offerings, indicating strong customer engagement and revenue potential [14][15] Strategic Initiatives - **Expansion of OnStar Services**: The OnStar platform is evolving to include features like remote vehicle control, security services, and AI-driven functionalities, enhancing customer experience and engagement [12][13][30] - **Autonomous Driving Strategy**: GM is preparing for the launch of Level 3 autonomy with the Cadillac Escalade IQ in 2028, which is expected to create significant revenue opportunities [45][47] - **Global Expansion**: The company is expanding its services internationally, with a focus on markets like South Korea, the Middle East, and Europe [26] Market Conditions - **Regulatory Environment**: GM is adapting to changes in U.S. regulations, including the rollback of emission standards, which allows for a focus on higher-margin internal combustion engine (ICE) vehicles [53][56] - **Demand Environment**: Despite concerns about consumer demand due to higher gas prices, GM reports stable sales and a strong product portfolio that includes affordable vehicles [62][63] Capital Allocation - **Investment Strategy**: GM plans to increase capital expenditures to $10 billion-$12 billion for 2026 and 2027, focusing on product investment and manufacturing improvements [71][75] - **Shareholder Returns**: The company is actively repurchasing shares, viewing its stock as undervalued compared to historical and industry benchmarks [80] Additional Insights - **Customer Retention**: The company has seen a 30%-40% renewal rate for its Super Cruise subscription, with factors influencing non-renewals including local driving habits and limited highway use [41][42] - **AI Integration**: GM is exploring AI applications across various business functions to enhance efficiency and reduce costs [50][51] This summary encapsulates the key points discussed during the conference call, highlighting GM's strategic focus on digital revenue, customer engagement, and market adaptability.

Summary of Dow Chemical's 2026 Conference Call Company Overview - **Company**: Dow Chemical (NYSE: DOW) - **CEO**: Jim Fitterling, CEO since 2018, with a long tenure at Dow since 1984 Key Industry Insights - **Market Dynamics**: The underlying demand conditions remain largely unchanged, but supply situations are evolving positively, impacting order books favorably [3][4] - **Polyethylene Pricing**: A $0.10 per pound price increase for polyethylene was announced globally in March, with an additional increase planned for April [4] - **Inventory Levels**: Industry inventory is below the five-year average, indicating strong working capital discipline and three years of destocking [4][21] - **Global Logistics**: Up to 50% of polyethylene supply is offline or constrained due to the Middle East conflict, leading to historically low inventory levels across the value chain [5] Financial Performance and Projections - **EBITDA Improvement**: Targeting approximately $3 billion of EBITDA uplift over the next few years, with $500 million in cost savings expected by the end of the year [8][9] - **Transform to Outperform Initiative**: Expected to deliver at least $2 billion in near-term EBITDA improvements, with $500 million anticipated this year [9][10] - **Cost Structure**: The completion of cost efforts and asset actions is projected to provide a $1 billion EBITDA improvement in 2026 [9] Strategic Actions - **Self-Help Measures**: Ongoing self-help actions are progressing well, focusing on cost structure and growth strategies [2][3] - **Operational Efficiency**: Plans to shut down high-cost upstream assets to strengthen competitive positioning [9] - **AI and Automation**: Implementing AI and automation to redesign workflows and improve operational efficiency [10][11] Customer and Market Engagement - **Customer Demand**: Strong demand from Asian customers, with Dow's order books booked out as much as possible [46][55] - **Regional Dynamics**: The company is monitoring demand post-Lunar New Year in Asia, which typically sees strong demand [57] Challenges and Risks - **Middle East Conflict**: The ongoing conflict has created significant supply chain pressures, with potential long-term impacts on operations and pricing [14][28] - **Naphtha Pricing**: Rising naphtha prices are affecting high-cost producers, which could lead to margin restoration in Europe [35][42] Future Outlook - **Volume Growth**: Limited volume growth expected in specialty plastics due to slower housing demand, but strong demand in electrical infrastructure and telecommunications is anticipated [81][87] - **Cash Flow Management**: Aiming for $5 billion in EBITDA generation, with a conservative estimate of 50% translating to cash flows [127] Conclusion - Dow Chemical is focused on navigating current market challenges while implementing strategic initiatives to enhance operational efficiency and financial performance. The company remains optimistic about future demand and pricing dynamics, particularly in the context of ongoing geopolitical tensions and evolving supply chain conditions.

Summary of Dow's 2026 Conference Call Company Overview - **Company**: Dow (NYSE:DOW) - **Date of Conference**: March 18, 2026 - **CEO**: Jim Fitterling, CEO since 2018, with a long tenure at Dow since 1984 Key Market Insights - **Macroeconomic Landscape**: Dow is focused on internal actions amidst geopolitical tensions, particularly in the Middle East, and is adapting to changing macroeconomic conditions for 2026 [2][3] - **Self-Help Actions**: Ongoing self-help measures are yielding positive results, with a focus on cost structure and business transformation [3][4] - **Polyethylene Market**: January saw record high sales volumes for polyethylene, with a global price increase of $0.10 per pound announced in March, and an additional increase of $0.15 per pound in North America [4][5] Supply Chain and Pricing Dynamics - **Supply Constraints**: Up to 50% of polyethylene supply is offline or constrained due to Middle East events, leading to historically low inventory levels across the value chain [5][6] - **Feedstock Prices**: Rising feedstock prices, particularly naphtha in Asia, are impacting the global cost curve and leading to operating rate reductions in high-cost assets [4][5] - **Logistics Uncertainty**: Global logistics have become uncertain, affecting supply chains and pricing strategies [5][6] Financial Performance and Projections - **EBITDA Improvement**: Targeted actions are expected to deliver approximately $3 billion in EBITDA uplift over the next few years, with $500 million in cost savings anticipated by the end of 2026 [7][8] - **Transform to Outperform Initiative**: This initiative aims for at least $2 billion in near-term EBITDA improvements, with $500 million expected this year [8][9] - **Cash Flow Management**: Dow aims for $5 billion in EBITDA generation, with a conservative estimate of 50% translating to cash flows, maintaining CapEx at $2.5 billion [131][132] Strategic Initiatives - **Operational Efficiency**: Dow is consolidating executive roles to unify working capital ownership and enhance innovation [9][10] - **Customer Partnerships**: Upgrading commercial fundamentals and raw material sourcing to better meet customer needs [10][11] - **Sustainable Growth**: Evaluating target sites for additional productivity and growth improvements [10][11] Regional Market Dynamics - **Europe vs. Asia**: The competitive landscape in Europe is improving due to higher co-product values, while Asia's demand post-Lunar New Year remains uncertain but traditionally strong [6][60] - **Ethylene Production**: Dow's integrated ethylene production in the Americas is a significant advantage, with 25 billion pounds of advantaged ethylene capacity [71][72] Specialty Plastics Outlook - **Volume Growth**: Specialty plastics, particularly in wiring and cable applications, are expected to see good volume growth, while housing-related elastomers may face slower demand [85][91] Challenges and Risks - **Middle East Conflict**: The ongoing conflict is causing significant supply chain disruptions and uncertainty in pricing and logistics [12][30] - **Sadara Operations**: Dow's Sadara facility is experiencing reduced rates due to inventory constraints, with a focus on managing financial responsibilities with Aramco [138][145] Conclusion - **Long-Term Resilience**: Dow is committed to maintaining operational and financial discipline while navigating current market challenges to enhance shareholder value [10][11]

Union Pacific (NYSE:UNP) 2026 Conference Summary Company Overview - **Company**: Union Pacific - **Date**: March 18, 2026 - **Speakers**: Jim Vena (CEO), Jennifer Hamann (CFO) Key Points Industry and Company Performance - Union Pacific ended the year as the safest Class I railroad based on Federal Railroad Administration (FRA) statistics, with a focus on safety and service improvements [12][13] - The railroad industry had its best year in 2025, with Union Pacific achieving a 24% reduction in the number of trains operated while handling increased traffic [13] - Union Pacific's terminal capacity has improved, with the Englewood terminal in Houston increasing from 2,200 to over 3,000 cars capability [13] Operational Metrics - Freight car velocity has improved, leading to reduced inventory needs for customers [15] - The operating ratio has been optimized, reflecting strong workforce productivity and operational efficiency [16] - In the first quarter of 2026, Union Pacific reported flat car loadings, with intermodal and automotive segments facing challenges, while industrial loads increased by 4% [18][19] Financial Insights - Fuel prices have risen from an expected $2.35 to approximately $2.70 per gallon, impacting expenses for the quarter [20] - The company anticipates about $30 million in merger costs for the quarter [21] - Capital expenditures for the year are projected at $3.3 billion, reflecting a strategic approach to investment [52] Merger and Strategic Outlook - Union Pacific is in the process of merging with Norfolk Southern, with a strong focus on enhancing service levels and operational efficiency [23][58] - The merger is expected to provide a competitive advantage, allowing for improved service and cost efficiency [23][58] - The company is committed to addressing regulatory concerns and stakeholder feedback during the merger review process [55][56] Market Conditions and Demand - Demand for industrial products is showing positive growth, particularly in the Texas Gulf Coast region, while residential housing construction remains weak [19] - The company is optimistic about maintaining service quality and customer communication to support business growth [48] Environmental Considerations - Union Pacific emphasizes its environmental efficiency, stating that rail transport is 70% more greenhouse gas efficient than trucking [83] - The anticipated increase in traffic due to the merger is not expected to significantly impact communities, as operational efficiencies have already reduced the number of trains [84][86] Cultural Integration - The merger with Norfolk Southern is expected to bring together two strong cultures focused on service and safety [90] - Union Pacific management has engaged with Norfolk Southern employees to ensure a smooth integration process [92] Additional Insights - The company is prepared to address competitive pressures from other major railroads, emphasizing the strength of its network and operational capabilities [80] - Union Pacific is open to reciprocal switching and committed gateways to enhance service offerings and competition [74][75] This summary encapsulates the key discussions and insights from the Union Pacific conference, highlighting the company's operational performance, strategic initiatives, and market outlook.

Summary of Protagonist Therapeutics Conference Call Company Overview - **Company**: Protagonist Therapeutics (NasdaqGM:PTGX) - **Key Product**: ICOTYDE, an oral peptide-targeted therapy for moderate-to-severe plaque psoriasis Key Industry and Company Insights FDA Approval Announcement - Protagonist announced FDA approval of ICOTYDE for treating moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older who weigh at least 40 kg [2][4] - ICOTYDE is the first oral peptide-targeted therapy that blocks the IL-23 pathway by targeting the IL-23 receptor, contrasting with existing injectable antibodies that target the IL-23 ligand [4][6] Clinical Development and Efficacy - The approval was supported by a comprehensive phase 3 program involving approximately 2,500 patients across four studies, meeting all primary endpoints and demonstrating a favorable safety profile [7][9] - ICOTYDE has a broad label based on studies in both adults and adolescents, including head-to-head studies showing superiority to the active comparator, Sotyktu [8] Financial Implications - The approval triggers a $50 million milestone payment from Johnson & Johnson (J&J) and initiates a royalty-based revenue stream [10] - Protagonist has earned a total of $387 million in milestone payments since the collaboration with J&J began in 2017, with an additional $580 million in potential future milestones [10][11] - The royalty structure includes tiered royalties ranging from 6% to 10% on global net sales, with a weighted average of 7.25% at $4 billion in annual sales [12] Strategic Partnerships - Protagonist emphasizes the importance of its collaboration with J&J, which is responsible for commercialization and ongoing clinical trials of ICOTYDE [13] - The partnership has been described as a win-win, highlighting the potential blockbuster category of ICOTYDE [13] Pipeline and Future Developments Additional Assets - Protagonist is expecting FDA approval for rusfertide, a hepcidin mimetic for polycythemia vera, in the third quarter of the year [14][15] - The company is developing new R&D assets, including an oral IL-17 peptide antagonist (PN881) and an oral triple GLP GIP GCG agonist (PN477) for obesity [16][17] Financial Position and Shareholder Value - Protagonist aims to fund its R&D programs without equity offerings, focusing on returning capital to shareholders through potential share buybacks [19][20] - The company is exploring partnerships for its IL-17 and obesity programs, with ongoing dialogues with multiple parties [107] Market Position and Competitive Landscape - Protagonist believes ICOTYDE can capture market share from existing injectables and attract patients currently not on treatment due to aversion to injections [53][54] - The company is focused on differentiating its products in a competitive landscape, particularly in the obesity space where unmet needs exist [77][96] Conclusion - The approval of ICOTYDE marks a significant milestone for Protagonist, validating its peptide technology platform and setting the stage for future growth and product-driven cycles [20][22] - The company is well-positioned financially and strategically to expand its pipeline and enhance shareholder value through innovative therapies and partnerships.

Summary of Minerva Neurosciences Conference Call Company Overview - **Company**: Minerva Neurosciences (NasdaqCM:NERV) - **Focus**: Development of roluperidone, a potential treatment for schizophrenia, specifically targeting negative symptoms [1][2] Industry Context - **Schizophrenia Symptoms**: Schizophrenia is characterized by three types of symptoms: positive, negative, and cognitive deficits. Negative symptoms significantly impair quality of life and are currently not effectively treated by existing antipsychotics [2][3][4] - **Negative Symptoms**: These include avolition (lack of motivation), which is crucial for patient functioning and quality of life. Current treatments do not address these symptoms adequately, leading to a significant unmet medical need [5][6][7] Core Points and Arguments - **Treatment Gap**: There is no approved treatment for negative symptoms of schizophrenia in the U.S. as of now, and existing antipsychotics may worsen these symptoms [4][5] - **Clinical Trial Design**: The company emphasizes the need for innovative trial designs to assess the efficacy of treatments for negative symptoms, suggesting that traditional methods may not be suitable [8][9] - **Pharmacology of Roluperidone**: Roluperidone works through mechanisms that do not block dopamine, which is believed to help maintain stability in positive symptoms while improving negative symptoms [16][17] - **Efficacy Data**: In clinical trials, roluperidone showed significant improvements in negative symptoms and functioning, with a low relapse rate when used as monotherapy. The drug was well-tolerated with no significant side effects [22][24][23] Important Data Points - **Clinical Trial Results**: - The primary endpoint was assessed using the PANSS scale, with significant improvements noted at week 12. The 64 mg dose showed stronger effects compared to the 32 mg dose [19][20] - The first study had a p-value of 0.0001, indicating strong efficacy, while the second study showed a nominal improvement for the 64 mg dose [20][21] - **Patient Population**: Over 800 patients participated in the trials, with a focus on those with stable positive symptoms and significant negative symptoms [17] Regulatory Considerations - **FDA Interactions**: The company has engaged in discussions with the FDA regarding trial design and endpoints, aiming to establish a clear path for approval given the lack of existing treatments for negative symptoms [25][26] - **Study Design**: The upcoming study will compare roluperidone to commonly prescribed antipsychotics, using a double-dummy design to maintain blinding [28] Future Outlook - **Timeline for Results**: The first patient in the new study is expected to be enrolled in Q2 of the current year, with top-line results anticipated in the second half of next year [41][42] - **Regulatory Submission**: Following the results, the company plans to re-engage with the FDA regarding NDA submission [42] Additional Considerations - **Clinical Meaningfulness**: The company is working to establish clinically meaningful effect sizes in collaboration with the FDA, given the absence of approved treatments for negative symptoms [30][31] - **Relapse Assessment**: The study will include psychometric endpoints and hard clinical endpoints to assess relapse rates and overall patient safety [39][40]